25.8 C
Delhi
Tuesday, April 1, 2025

Glenmark Pharmaceuticals receives tentative ANDA approval for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%

Must read

">Instaa PR<span class="bp-verified-badge"></span>
Instaa PRhttp://instaapr.com
InstaaPR refers to Instant PR, a premium automated DIY marketing platform, where we revolutionize the way Digital PR functions. We provide effective and efficient online reach to increase your brand's online presence. The process is primarily driven by a wider distribution of brand stories based on relevance. It helps in targeting the content to the apt audience. InstaaPR enables enterprises in building a positive brand image and vibrancy on the web. Amidst the lockdown, InstaaPR is helping several clients with cost-effective PR Campaigns to maintain services and to keep the communication/branding continuity alive.
Reading Time: < 1 minute

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%, the generic version of Enstilar®1 Foam, 0.005%|0.064%, of Leo Pharma AS.

According to IQVIA™sales data for the 12 month period ending March 2022, the Enstilar® Foam, 0.005%|0.064% market2 achieved annual sales of approximately $115.2 million*.

Glenmark’s current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Views: 0

- Advertisement -spot_img

More articles

- Advertisement -spot_img

Latest article